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of disorders.
Patients and methods: All children less than 18 years of age with PIDs
who were transplanted at Apollo Speciality Cancer hospital, Chennai from
2008 to 2016 were included in the study. Each of the PIDs were analyzed in
terms of the type of graft used, conditioning regimen, their rates of
engraftment, presence of co-morbidities at the time of HSCT, propensity
for GVHD and causes of mortality.
Results: A total of 62 PID transplants have been performed at our centre of
which 37 were T cell defects, 3 B cell defects, 11 Phagocytic defects, 10
primary Haemophagocytic Lymphohistiocytosis (HLH), 2 Mendelian sus-
ceptibility to Mycobacterial Disease (MSMD). Haploidentical HSCT was
offered in 13 children. The conditioning regimen was myeloablative in
children with Wiskott Aldrich Syndrome (WAS), Hyper IgM, and Chronic
Granulomatous Disease (CGD) with ﬂudarabine and buslphan. All children
with Severe Combined Immune Deﬁciency (SCID), Haemophagocytic
Lymphohistiocytosis (HLH), Common Variable Immune Deﬁciency (CVID),
Leucocyte Adhesion Defect (LAD) were treated with a reduced intensity
conditioning using ﬂudarabine and treosulphan. All haploidentical trans-
plantation were done based on the same reduced intensity protocol with
post transplant cyclophosphamide.
Co-morbidities at the time of HSCT namely infections, disseminated BCG
infection and failure to thrive was noted in 62.5% of the SCID babies. All
childrenwith WAS and Hyper IgM syndrome had eczema, bloody diarrhea
or pneumonia and refractory immune cytopenias. Children with CGD had
previous fungal granulomas or tuberculosis, hildren with CVID had bron-
chiectasis and children with LAD had non-healing ulcers.
Among children with SCID, most common cause of death was bacterial
sepsis whilst children with WAS died due to pulmonary haemorrhage
associated with immune cytopenias. Among those with HLH, 1 died of
immune haemolysis and the other 2 who were less than 6 months of age
died of pulmonary haemorrhage. Graft versus host disease (GVHD) was
the cause of death in 2 children and late cytomegaloviral (CMV) infection
resulted in death in 3 children. Primary graft failure was seen in 2 chil-
dren resulting in an overall survival rate among all children with PIDs
of 62%.
Conclusion: This is the ﬁrst series in India with survival rates of 62% in
children with Primary Immune Deﬁciency Disorders. Conditioning regi-
mens need to be chosen based on the genotype of an individual child. The
pre-engraftment phase is critical in babies with SCID due to maximum
mortality risk due to bacterial sepsis during this phase. Wiskott-Aldrich
syndrome poses unique challenges due to immune dysregulation and
these children need to be monitored for late immune cytopenias affecting
mortality in over 50%. GVHD is a predominant problem in children with
CGD with a risk of 80%. In children with primary HLH and less than 6
months of age, acute pulmonary haemorrhage is a risk factor affecting
mortality. In all these children, CMV viral load needs to be monitored and
treated early. Haploidentical HSCT is a feasible option in children with no
matched family donors with success rates on par with unrelated donor
HSCT.
SCT-1_V1.8
ALLOGENIC HEMATOPOEITIC STEM CELL TRANSPLANT FOR HIGH RISK
ACUTE PEDIATRIC LEUKEMIA: SINGLE CENTER EXPERIENCE
Vipin Khandelwal, Dharma Choudhary, Gaurav Kharya, Sanjeev
Sharma, Divya Doval, Bharti Sharma, Rasika Setia, Anil Handoo, Tina
Dadu. Hemato-Oncology and Bone Marrow Transplant, Transfusion
Medicine, Haematology, BLK Superspeciality Hospital, Delhi, India
Objectives: Aim of the study is to analyze retrospectively the outcome of
allogenic hematopoeitic stem cell transplant (HSCT) for High Risk Acute
Pediatric Leukemia.
Methods: Retrospective data was analyzed for patient who underwent
allogenic HSCTat our center from January 2008 to June 2016. After a signed
informed consent a total of 42 transplants were done for 41 patients;
Median age was 16 years (range 3-21). The diagnosis was: acute
lymphoblastic leukemia in 26(63%) patients, acute myeloid leukemia
14(34%), and Acute Promyelocytic Leukemia in one. 33% were in ﬁrst
remission (CR1), 40% in second (CR2), and 27 % in third or with refractory
disease (CR3). Transplant type: MSD-30; Haploidentical HSCT-10& MUD-2. Conditioning regimen: Cy/TBI- 13; BU/Cy- 13; Flu/Mel- 4; Flu/Cy/TBI- 6;
Bu/ﬂu/Cy -3; In vitro T cell depletion and Flu/Mel/ATG/Thiotepa - 2 pa-
tients; Flu/AraC/Ida/Mel-1. Graft versus host disease (GVHD) prophylaxis
was Cyclosporine and Methotrexate in 31; PTCy with Tacrolimus/MMF in
9, and Tacrolimus/MMF in 2 patients.
Results: Out of 42 transplants, 5 patients received bone marrow, 37
patients received G- CSF mobilized peripheral blood stem cells. A me-
dian 7 million of CD34+ cells/kg was infused. A total of 39 transplants
(93%) engrafted. Median time for Neutrophil and platelet engraftment
was 11 days and 17 days respectively. Seven patient developed hemor-
rhagic cystitis. Acute graft GVHD (GR II e IV) was seen in 12(29%) and
chronic GVHD in 3 patients. CMV reactivation was seen in 5 patients and
was treated with Gancyclovir. Chimerism at day + 100 was available in
25(60%) cases; all of them had full donor hematopoiesis.Primary
rejection was seen in 2 patients and secondary rejection in 1 patient.
Fourteen patients (34%) have died, the causes were; relapse of leukemia
(n: 7), Infection (n: 4), GVHD (n: 3).Median follow up period was 250
days with overall survival (OS) for the whole group 66%. Discriminated
OS according to remission status was 71% in CR1, 70% in CR2 and 54% in
CR3.
Conclusion: Allogenic HSCT is a suitable option in pediatric high risk
leukemia and shows encouraging resultsSCT-1_V1.9
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Introduction: The major barriers to successful haplo-identical stem cell
transplantation (haplo-HSCT) in leukemia are disease relapse, graft
rejection and delayed immune recovery in settings of T-cell depletion and
acute GVHD in case of T-cell replete transplant. Leukemia relapse remains
one of the major causes of treatment failure. Graft manipulation with se-
lective removal of TCR a/b and CD 19 positive lymphocytes have been
developed to address these conundrums of haplo-HSCT.
Methods: We retrospectively reviewed clinical outcomes of haplo- HSCT
with TCR a/b and CD 19 depleted graft in pediatric patients with
leukemia.
Results: Eight patients (male n¼5; female n¼3) with a median age of 45
months (11 to 68) underwent 9 haplo-HSCT with TCR a/b and CD 19
depletion including a salvage transplantation (father donor in 7 and
mother in 1). Seven patients had relapsed acute lymphoid leukemia,
while one patient had relapsed acute myeloid leukemia. Myeloablative
conditioning regimens were used including Fludarabine-TBI-Etoposide,
Fludarabine-Busulphan-Melphalan and Fludarabine-ATG-TBI. Pre-
transplant rituximab was administered in 5 patients on day-1 to
decrease the risk of EBV associated PTLD. Stem cell source in all the
transplants was PBSC manipulated by TCR a/b and CD 19 depletion. Only
three received post-transplant GVHD prophylaxis. The graft contained a
median of 17.7106/kg (range 12.5 - 25.3) CD 34 cells, 0.04106/kg
(range 0.02 - 0.93) TCR a/b and 8.1106/kg (range 2.8 - 68.8) TCR g/
d cells. Primary neutrophil engraftment was achieved in all eight
transplantations and the median day of neutrophil engraftment was 12
days (range 9 - 20). Cumulative incidence of acute GVHD grade II-IV was
37.5% and of none of the patient developed grade III-IV acute GVHD.
Three patients developed CMV reactivation. One patient had secondary
graft failure on day +33 post transplantation and subsequently suc-
cumbed to infectious complications following a salvage transplant. One
patient with ALL had disease relapse, on day +236. Immune reconsti-
tution was robust with NK cells recovering the fastest (median of 213/uL
at day +21). With a median follow up of 472 days (range 153 - 635);
event free survival (EFS) was 75%.
Conclusion: Our data suggest that TCR a/b and CD 19 depletion for graft
manipulation in haplo-HSCT for acute leukemia results in good engraft-
ment, low rejection rates, low incidence of acute GVHD and, most strik-
ingly, low relapse rates.
